Publication
Valor prognóstico da expressão por imuno-histoquímica do c-erb-2: em doentes sob terapêutica adjuvante com Tamoxifeno por carcinoma primário da mama
dc.contributor.author | Antunes, A | |
dc.contributor.author | Silva, T | |
dc.contributor.author | Godinho, I | |
dc.contributor.author | Amaral, A | |
dc.contributor.author | Oliveira, CF | |
dc.date.accessioned | 2008-11-18T11:46:57Z | |
dc.date.available | 2008-11-18T11:46:57Z | |
dc.date.issued | 2004 | |
dc.description.abstract | INTRODUCTION: The c-erb2 proto-oncogene is a member of the epidermal growth factor receptor family and has been associated with a more aggressive breast tumour biology and resistance to some types of treatments. AIMS: To evaluate the prognostic value of c-erb-2 receptor, from primary breast cancer on tamoxifen therapy. METHODS: We examined 66 paraffin-embedded sections from primary breast cancers. Patients were treated with surgery plus adjuvant treatment with tamoxifen; 58% had also received chemotherapy and/or radiotherapy. Membrane staining for c-erb-2 was evaluated by immunohistochemistry and overall survival and relapse-free survival were compared between positives and negatives for c-erb-2. RESULTS: 43,9% of tumours over expressed c-erb-2 receptor, but this was not associated with a worse prognosis on overall survival either on relapse free-survival, with a p value of 0,15 and 0,2 respectively. CONCLUSIONS: There is not any advantage to determine c-erb-2 as a prognostic factor on overall survival either on relapse free-survival. Attending the homogenous characteristics between both groups with any statistical differences according age. | en |
dc.identifier.citation | Acta Med Port. 2004 Jul-Aug;17(4):271-6 | en |
dc.identifier.uri | http://hdl.handle.net/10400.4/39 | |
dc.language.iso | por | en |
dc.subject | Neoplasias da Mama | en |
dc.subject | Tamoxifeno | en |
dc.subject | Imunohistoquímica | en |
dc.title | Valor prognóstico da expressão por imuno-histoquímica do c-erb-2: em doentes sob terapêutica adjuvante com Tamoxifeno por carcinoma primário da mama | en |
dc.title.alternative | Prognostic value of c-erb-2 immunohistochemistry expression in patients with primary breast cancer and adjuvant treatment with tamoxifen | en |
dc.type | journal article | |
dspace.entity.type | Publication | |
rcaap.rights | openAccess | |
rcaap.type | article | en |